Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest VEGF receptors Stories

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...

2013-11-29 14:37:54

A study led by researchers at Boston University School of Medicine (BUSM) demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling. Angiogenesis creates new blood vessels in a process that can lead to the onset and progression of several diseases such as cancer and age-related macular degeneration. Vascular endothelial growth...

2013-04-29 15:20:35

Scientific collaborators from Yale School of Medicine and University College London (UCL) have uncovered the molecular pathway by which new arteries may form after heart attacks, strokes and other acute illnesses bypassing arteries that are blocked. Their study appears in the April 29 issue of Developmental Cell. Arteries form in utero and during development, but can also form in adults when organs become deprived of oxygen – for example, after a heart attack. The organs release a...

2012-03-29 21:48:03

Max Planck researchers unravel a critical regulatory mechanism controlling blood vessel growth that might help solve drug resistance problems in the future Angiogenesis, the growth of new blood vessels, is a complex process during which different signalling proteins interact with each other in a highly coordinated fashion. The growth factor VEGF and the Notch signalling pathway both play important roles in this process. VEGF promotes vessel growth by binding to its receptor, VEGFR2, while...

2012-03-05 23:13:39

Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine. Current therapy for glioblastoma, the most prevalent malignant brain tumor in adults, includes targeting a protein called VEGF, which promotes the growth of blood vessels to the tumor. Unfortunately, in most glioblastoma patients treated with anti-VEGF drugs, tumors return shortly after treatment. Through...

2012-02-07 12:08:41

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients. The incidence of fatal complications was 1.5 percent in patients who received any of the three drugs, which block the vascular endothelial growth factor (VEGF) tyrosine kinase receptors...

2012-01-30 06:00:00

MELBOURNE, Australia, Jan. 30, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. Importantly the data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C,...

2012-01-08 16:30:00

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre. The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also...

2011-10-31 08:50:00

MELBOURNE, Australia, Oct. 31, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials of VGX-100. The first trial (Phase I) will study VGX-100 in patients with a variety of late stage cancers. "The FDA's acceptance of our IND represents an extremely important...

2011-06-06 18:38:00

MELBOURNE, Australia, June 6, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR) announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin® with increases in plasma VEGF-C and D concentrations. The poster presentation entitled "The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer (mCRC)" is available on...